Welcome to our dedicated page for Zeo ScientifiX news (Ticker: OCEL), a resource for investors and traders seeking the latest updates and insights on Zeo ScientifiX stock.
Zeo ScientifiX, Inc. (OTCQB:ZEOX) is a clinical-stage biopharmaceutical company specializing in the development of innovative biological therapeutics for chronic diseases. Founded in 2011 and headquartered at Nova Southeastern University's Collaborative Center for Research in Davie, Florida, Zeo ScientifiX was formerly known as Organicell Regenerative Medicine, Inc. The company underwent a rebranding in March 2024 to better reflect its mission and cutting-edge research initiatives.
The core of Zeo ScientifiX's business lies in the development of proprietary products derived from perinatal, allogenic, and autologous sources. These products are meticulously manufactured in an FDA-registered, cGMP-compliant laboratory to retain essential bioactive components such as exosomes, hyaluronic acid, and proteins without the addition of any other substances or diluents.
Notably, Zeo ScientifiX has made significant strides in its clinical research programs. Their flagship product, Zofin™, which contains high concentrations of nanoparticles including exosomes, growth factors, and bio-active proteins, has shown promising safety outcomes across multiple Phase 1 studies, including trials for knee osteoarthritis and moderate-to-severe COVID-19. With no reported therapy-related safety events, the company is positioned to advance to larger Phase 2 studies in 2024.
In recent developments, Zeo ScientifiX announced a 1-for-200 reverse split of its common stock, aimed at improving marketability and attracting institutional investors. The company also welcomed Howard L. Golub, MD, PhD, as its new Executive Vice President and Chief Science Officer, bringing a wealth of experience in clinical research and drug development.
Zeo ScientifiX's commitment to pioneering research is further strengthened by its strategic partnerships, including a collaboration with Regenerative Care Network to explore the therapeutic benefits of Zofin™ for heart failure patients. The company continues to enhance its leadership team and expand its research capabilities, aiming to redefine the standard of care for chronic diseases through innovative biologic therapies.
For more information, please visit https://zeoscientifix.com/.
Organicell Regenerative Medicine (OTCQB: OCEL) has announced that its long COVID clinical trial is now active and enrolling patients in Miami and Los Angeles. The company has treated multiple patients for COVID under FDA programs, demonstrating promising results with its therapeutic Zofin, which may reduce inflammation and improve lung health. With over 140 million globally affected by long COVID, Organicell seeks government support to expedite the development of Zofin for broader use in treatment.
Organicell Regenerative Medicine (OTCQB:OCEL) has announced the activation of a clinical trial site at Mayo Clinic, Phoenix, for a Phase I/II study on Chronic Obstructive Pulmonary Disease (COPD). The trial will evaluate the safety and efficacy of Zofin, an intravenous infusion therapy, aimed at improving pulmonary function in COPD patients. This trial is particularly timely as COPD patients are at increased risk for severe outcomes from COVID-19. With COPD affecting around 10% of individuals over 45, the potential impact of this research is significant.
Organicell Regenerative Medicine (OTCQB:OCEL) announced the election of several new independent board members, enhancing its leadership with diverse expertise. Dr. Bhupendra Kumar Modi was appointed Chairman, bringing significant experience in healthcare and wellness. Other notable members include Chuck Bretz as Vice Chairman, and John Chistie, who has a vast financial background. The new appointments aim to improve corporate governance and strategic direction, indicating the company's focus on leveraging experience for its regenerative medicine initiatives.
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) has appointed new key executives, including Ryan Likes as Chief Operating Officer, David Aciego as Chief Information Officer, and Jacqueline Domenech as Director of Finance.
Likes brings legal and operational expertise from Turner Broadcasting and Televisa USA. Aciego enhances technical capabilities by developing a HIPAA-compliant ERP and CRM system. Domenech adds financial oversight with over 10 years of healthcare experience. These strategic hires aim to improve company efficiency, manage risk, and support growth amid ongoing development in biological therapeutics.
Organicell Regenerative Medicine (OTCQB:OCEL) announced its entry into the skincare and haircare industries via a partnership with BeautyHealth's Hydrafacial (NASDAQ:SKIN). This collaboration aims to create an exosome booster for Hydrafacial's patented device, enhancing its efficacy by reducing inflammation and promoting collagen and elastin production. CEO Matt Sinnreich highlighted this partnership as a stepping stone towards expanding the company’s research into hair restoration and skincare applications. The partnership grants Hydrafacial exclusivity for their applications, positioning Organicell for future growth in these markets.
The Beauty Health Company (NASDAQ:SKIN) has partnered with Organicell to develop a groundbreaking exosome booster targeting aging and inflammation. This innovative product will utilize Organicell's advanced exosome technology, harnessing over 300 cytokines and growth factors. With a rapid development process, the booster is expected to enhance Hydrafacial's offerings and will launch in early 2024. This collaboration capitalizes on co-creation, allowing the company to stay ahead in the skincare market by responding quickly to consumer demands for regenerative treatments.
FAQ
What is the market cap of Zeo ScientifiX (OCEL)?
What is Zeo ScientifiX, Inc.?
What are the company's main products?
What recent developments has the company announced?
What clinical trials are Zeo ScientifiX currently conducting?
Where is Zeo ScientifiX headquartered?
What is the ticker symbol for Zeo ScientifiX?
When was Zeo ScientifiX founded?
What are the company's recent achievements?
Who is Zeo ScientifiX's Chief Science Officer?
What partnerships does Zeo ScientifiX have?
